The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Launched by NUVANCE HEALTH · May 22, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the role of small molecules called microRNAs (miRNAs) in pancreatic cancer. Researchers believe that measuring specific miRNAs in the blood of patients with pancreatic cancer could help in diagnosing the disease earlier and understanding how patients respond to treatments. This is especially important for those with advanced stages of pancreatic cancer, as it may provide valuable information about the progression of the disease and the best treatment options.

To be eligible for this trial, participants need to have a confirmed diagnosis of pancreatic adenocarcinoma that cannot be operated on initially, which includes certain advanced cases or those that have come back after surgery. They should also have measurable disease and be in relatively good health according to specific criteria. Participants will be asked to provide blood samples and other information to help with the study. It’s important to note that those who have already had treatment for metastatic pancreatic cancer or are currently being treated for another cancer may not be able to participate. Overall, this trial aims to improve how pancreatic cancer is diagnosed and treated, potentially leading to better outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have biopsy proven adenocarcinoma of the pancreas
• • Have initially inoperable disease, classified as either locally advanced or metastatic disease
• • Recurrent disease after a Whipple procedure is allowed
• • Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
• • Have radiographically measurable disease
• • Have an ECOG performance status of 2 or less
• • Be willing to contribute the required information and specimens
• • Provide written signed consent to participate
• Exclusion Criteria:
• • Having received prior anti-cancer treatments for metastatic pancreatic cancer
• • Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
• • Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable